The findings from this study have the potential to serve as a foundation for evaluating the current practices related to surgical procedures, systemic therapies, hyperthermic intraperitoneal chemotherapy, and referrals to geneticists for OC patients. By identifying the strengths and weaknesses of the existing care, this project intends to generate valuable insights that can lead to the implementation of quality parameters for the treatment of ovarian cancer in the country.
Patients ≥18 years old;
Newly diagnosed ovarian cancer stages IA to IVB, or persistent or recurrent disease from January 2021;
Irrespective of histology
Borderline tumors;
Pregnancy;
Synchronous tumor or second primary in the last 5 years (except thyroid cancer and non-melanoma skin cancer);